Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Hua Xi Kou Qiang Yi Xue Za Zhi ; 38(6): 637-641, 2020 Dec 01.
Article in Chinese | MEDLINE | ID: mdl-33377339

ABSTRACT

OBJECTIVE: To compare the anti-caries effect and safety of Er:YAG laser combined with fluoride and methylene blue-photodynamic therapy (MB-PDT). METHODS: A total of 28 rat dental caries models were established and randomly divided into seven groups: photodynamic therapy (PDT) group, laser combined with fluoride group, laser group, sodium fluoride group, and 0.9% saline control group. Spectrophotometric optical density was used to reflect the growth of Streptococcus mutans. Laser-induced fluorescence diagnostic (LF) instrument was utilized to detect the demineralization degree of dental caries. Histopathological sections were employed to observe the damage of dental pulp and buccal mucosa. RESULTS: The optical density (OD) value of the PDT and combination groups was significantly lower than that of other treatment groups (P<0.05). An increase in LF value and demineralization occurred in varying degrees with different treatment methods. Histopathological observation showed that pulp and buccal mucosa injury was more obvious in the combination group of 70 mw·cm⁻² and Er:YAG laser group compared with other groups. CONCLUSIONS: Under the same parameters, the combined group and PDT have good germicidal efficacy, but PDT has fewer adverse reactions and less damage. It is an effective and safe method for caries prevention.


Subject(s)
Dental Caries , Laser Therapy , Lasers, Solid-State , Photochemotherapy , Cariostatic Agents , Dental Caries/prevention & control , Fluorides , Humans , Methylene Blue
2.
Clin Exp Pharmacol Physiol ; 45(6): 514-524, 2018 06.
Article in English | MEDLINE | ID: mdl-29193272

ABSTRACT

This study was designed to investigate the possible synergism of amlodipine and candesartan on the reduction of blood pressure (BP) in hypertensive rats. The end organ protection was also observed. In acute experiment, spontaneously hypertensive rats (SHRs) were treated with intragastric administration of amlodipine (0.5, 1, 2, 3 mg/kg), candesartan (1, 2, 3, 4, 6, 8 mg/kg), and 14 different combinations to find the possible ratio of synergistic interaction. In two kidneys, one clip (2K1C) rats, the effects of amlodipine (1 mg/kg), canderastan (2 mg/kg) and their combination on BP reduction were also observed. In chronic study, SHRs were treated with amlodipine (1 mg/kg), candesartan (2 mg/kg), and their combination for 5 months. Organ damage evaluation was performed after BP recording. The probability sum test (q test) was used to evaluate the synergistic action. There is a synergistic interaction between amlodipine and candesartan on BP reduction. The optimal dose ratio is 1:2. The synergistic effect was also confirmed by 2K1C hypertensive rats. In chronic study, this combination (1:2) possessed an obvious synergism on the reduction of BP and BP variability (BPV) and protection on end organs. Multiple regression analysis showed that heart and aortic hypertrophy indexes and glomerular damage parameters were positively related to BP and BPV. In conclusion, combination of amlodipine and candesartan exhibited a potent antihypertensive effect and possessed an obvious synergism on BP reduction and organ protection in hypertension. The optimal proportion was 1:2. BP and BPV reduction may both importantly contribute to end organ protection.


Subject(s)
Amlodipine/adverse effects , Amlodipine/pharmacology , Antihypertensive Agents/adverse effects , Antihypertensive Agents/pharmacology , Benzimidazoles/adverse effects , Benzimidazoles/pharmacology , Blood Pressure/drug effects , Tetrazoles/adverse effects , Tetrazoles/pharmacology , Animals , Biphenyl Compounds , Dose-Response Relationship, Drug , Drug Synergism , Heart Rate/drug effects , Male , Rats , Rats, Sprague-Dawley , Time Factors
3.
Sci Rep ; 7: 40986, 2017 01 27.
Article in English | MEDLINE | ID: mdl-28128226

ABSTRACT

Susceptibility to motion sickness (MS) varies considerably among humans. However, the cause of such variation is unclear. Here, we used a classical genetic approach to obtain mouse strains highly sensitive and resistant to MS (SMS and RMS). Proteomics analysis revealed substantially lower swiprosin-1 expression in SMS mouse brains. Inducing MS via rotary stimulation decreased swiprosin-1 in the mouse brains. Swiprosin-1 knockout mice were much more sensitive to motion disturbance. Immunohistochemistry revealed strong swiprosin-1 expression in the vestibular nuclei (VN). Over-expressing swiprosin-1 in the VN of SMS mice decreased MS susceptibility. Down-regulating swiprosin-1 in the VN of RMS mice by RNAi increased MS susceptibility. Additional in vivo experiments revealed decreased swiprosin-1 expression by glutamate via the NMDA receptor. Glutamate increased neuronal excitability in SMS or swiprosin-1 knockout mice more prominently than in RMS or wild-type mice. These results indicate that swiprosin-1 in the VN is a critical determinant of the susceptibility to MS.


Subject(s)
Calcium-Binding Proteins/analysis , Motion Sickness/pathology , Vestibular Nuclei/pathology , Animals , Calcium-Binding Proteins/genetics , Immunohistochemistry , Mice, Knockout , Proteomics
4.
CNS Neurosci Ther ; 22(8): 715-22, 2016 08.
Article in English | MEDLINE | ID: mdl-27160425

ABSTRACT

BACKGROUND AND AIMS: Severe motion sickness is a huge obstacle for people conducting precise aviation, marine or emergency service tasks. The combination of scopolamine and d-amphetamine is most effective in preventing severe motion sickness. However, this combination is not included in any present pharmacopoeia due to the abuse liability of d-amphetamine. We wanted to find a combination to replace it for the treatment of severe motion sickness. METHODS AND RESULTS: We compared the efficacy of scopolamine, diphenhydramine, and granisetron (representing three classes of drugs) with different doses, and found that scopolamine was the most effective one. We also found scopolamine inhibited central nervous system at therapeutic doses and caused anxiety. Then, we combined it with different doses of psychostimulants (d-amphetamine, modafinil, caffeine) to find the best combination for motion sickness. The efficacy of scopolamine with modafinil (1 + 10 mg/kg) was equivalent to that of scopolamine with d-amphetamine (1 + 1 mg/kg); This combination also excited central nervous system and abolished the anxiety caused by scopolamine. CONCLUSIONS: The optimal dose ratio of scopolamine and modafinil is 1:10. This combination is beneficial for motion sickness and can abolish the side effects of scopolamine. So, it might be a good replacement of scopolamine and d-amphetamine for severe motion sickness.


Subject(s)
Central Nervous System Stimulants/therapeutic use , Cholinergic Antagonists/therapeutic use , Motion Sickness/prevention & control , Scopolamine/therapeutic use , Analysis of Variance , Animals , Benzhydryl Compounds/pharmacology , Caffeine/therapeutic use , Dextroamphetamine/pharmacology , Diphenhydramine/therapeutic use , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Combinations , Granisetron/therapeutic use , Locomotion/drug effects , Male , Mice , Mice, Inbred ICR , Modafinil , Motion Sickness/etiology , Rotation/adverse effects
5.
J Chemother ; 24(5): 257-67, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23182045

ABSTRACT

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality throughout the world. To investigate whether moxifloxacin monotherapy is associated with better clinical outcomes than other antibiotics recommended for CAP among adults with mild-to-moderate or severe CAP, we performed a meta-analysis. MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched for randomized control trials (RCTs). The efficacy and safety of moxifloxacin were compared with other antimicrobial agents used to treat CAP. Fourteen RCTs, consisting of 6923 total patients, were included in the meta-analysis. No difference was found regarding the incidence of adverse events and mortality between moxifloxacin and the compared regimens. We found that moxifloxacin is as effective and well-tolerated as other recommended antibiotics for the treatment of CAP and possesses a better pathogen eradication rate than beta-lactam-based therapy.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Aza Compounds/therapeutic use , Pneumonia, Bacterial/drug therapy , Quinolines/therapeutic use , Randomized Controlled Trials as Topic , Community-Acquired Infections/drug therapy , Fluoroquinolones , Humans , Moxifloxacin
6.
Mol Plant ; 5(3): 726-33, 2012 May.
Article in English | MEDLINE | ID: mdl-22311776

ABSTRACT

Arabidopsis cryptochrome 2 (CRY2) is a blue-light receptor mediating blue-light inhibition of hypocotyl elongation and photoperiodic promotion of floral initiation. CRY2 is a constitutive nuclear protein that undergoes blue-light-dependent phosphorylation, ubiquitination, photobody formation, and degradation in the nucleus, but the relationship between these blue-light-dependent events remains unclear. It has been proposed that CRY2 phosphorylation triggers a conformational change responsible for the subsequent ubiquitination and photobody formation, leading to CRY2 function and/or degradation. We tested this hypothesis by a structure-function study, using mutant CRY2-GFP fusion proteins expressed in transgenic Arabidopsis. We show that changes of lysine residues of the NLS (Nuclear Localization Signal) sequence of CRY2 to arginine residues partially impair the nuclear importation of the CRY2K541R and CRY2K554/5R mutant proteins, resulting in reduced phosphorylation, physiological activities, and degradation in response to blue light. In contrast to the wild-type CRY2 protein that forms photobodies exclusively in the nucleus, the CRY2K541R and CRY2K554/5R mutant proteins form protein bodies in both the nucleus and cytosol in response to blue light. These results suggest that photoexcited CRY2 molecules can aggregate to form photobody-like structure without the nucleus-dependent protein modifications or the association with the nuclear CRY2-interacting proteins. Taken together, the observation that CRY2 forms photobodies markedly faster than CRY2 phosphorylation in response to blue light, we hypothesize that the photoexcited cryptochromes form oligomers, preceding other biochemical changes of CRY2, to facilitate photobody formation, signal amplification, and propagation, as well as desensitization by degradation.


Subject(s)
Arabidopsis Proteins/chemistry , Arabidopsis Proteins/metabolism , Arabidopsis/metabolism , Arabidopsis/radiation effects , Cryptochromes/chemistry , Cryptochromes/metabolism , Light , Proteolysis/radiation effects , Amino Acid Sequence , Arabidopsis/genetics , Arabidopsis/growth & development , Cell Nucleus/metabolism , Cell Nucleus/radiation effects , Hypocotyl/growth & development , Hypocotyl/radiation effects , Lysine/metabolism , Molecular Sequence Data , Mutant Proteins/chemistry , Mutant Proteins/metabolism , Mutation/genetics , Nuclear Localization Signals/chemistry , Nuclear Localization Signals/metabolism , Phosphorylation/radiation effects , Plants, Genetically Modified , Protein Structure, Quaternary , Protein Transport/radiation effects
7.
J Antimicrob Chemother ; 67(2): 255-68, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22096042

ABSTRACT

Fosfomycin has attracted renewed interest for the treatment of lower urinary tract and even systemic infections caused by Gram-negative pathogens with resistance to traditionally used agents. The main concern regarding the clinical utility of fosfomycin refers to the potential for the emergence of resistance during therapy. In this review, we evaluate the available published evidence regarding the mechanisms and the frequency of in vitro mutational resistance to fosfomycin in Gram-negative pathogens. We also review data regarding the emergence of resistance in clinical studies of fosfomycin therapy in various infectious syndromes and data from studies that evaluate the evolution of fosfomycin resistance over time. There appears to be discordance between the high frequency of mutational resistance to fosfomycin in vitro and the lower extent of this phenomenon in clinical studies. This discordance could at least partly be attributed to a biological cost associated with common mutations that confer resistance to fosfomycin, including decreased growth rate and low adherence to epithelial cells for the resistant mutants. The development of resistance appears to be more frequent both in vitro and in clinical studies for Pseudomonas aeruginosa in comparison with Escherichia coli, whereas relevant data for other Enterobacteriaceae are relatively scarce. The urinary tract seems to provide a favourable environment for the use of fosfomycin with a low associated likelihood for the emergence of resistance, owing to high drug concentrations and acidic pH. Additional data are needed to further clarify the optimal use of fosfomycin for different infectious syndromes caused by contemporary multidrug-resistant pathogens.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Enterobacteriaceae/drug effects , Fosfomycin/pharmacology , Gram-Negative Bacterial Infections/microbiology , Pseudomonas aeruginosa/drug effects , Anti-Bacterial Agents/therapeutic use , Fosfomycin/therapeutic use , Gram-Negative Bacterial Infections/drug therapy , Humans , Mutation
8.
J Antibiot (Tokyo) ; 63(11): 657-9, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20877368

ABSTRACT

The objective of this paper was to investigate the in vitro effects of fusidic acid combined with fosfomycin against methicillin-resistant Staphylococcus aureus (MRSA). In all, 196 MRSA strains isolated from three clinical specimens of human infections from hospitals in China were used in this study. The checkerboard method was used to determine whether combinations act synergistically against these strains. The susceptibility results for fusidic acid and fosfomycin were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute. The combination of fusidic acid and fosfomycin demonstrated the following interactions: 87.76% (172/196) synergism, 12.24% (24/196) indifference and no antagonism was seen (minimum and maximum fractional inhibitory concentration index 0.14 and 0.75, respectively). Thus, combinations of fusidic acid and fosfomycin show synergism for most of the MRSA isolates tested in this study, and may be a future therapeutic alternative for infections caused by MRSA.


Subject(s)
Anti-Bacterial Agents/pharmacology , Fosfomycin/pharmacology , Fusidic Acid/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Anti-Bacterial Agents/administration & dosage , China , Drug Synergism , Drug Therapy, Combination , Fosfomycin/administration & dosage , Fusidic Acid/administration & dosage , Guidelines as Topic , Humans , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Microbial Sensitivity Tests , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology
9.
J Pharm Pharmacol ; 61(9): 1257-62, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19703377

ABSTRACT

OBJECTIVES: Iron plays an important role in the development of Pseudomonas aeruginosa biofilm. Here we evaluated effects of iron depletion on the antimicrobial activity of ceftazidime, tobramycin and ciprofloxacin against planktonic and biofilm Pseudomonas aeruginosa. METHODS: We tested the sensitivities of wild-type PAO1, type-IV pilus mutant PAO-DeltapilHIJK and the quorum-sensing mutant PAO-JP2 P. aeruginosa planktonic cultures and biofilms to antibiotics under iron-depleted conditions. KEY FINDINGS: In planktonic bacteria, the minimum concentration that inhibited visible growth (MIC) of ciprofloxacin was increased slightly in an iron-depleted environment in all three strains, whereas the MIC of tobramycin was similar in iron-depleted and control environments. The MIC of ceftazidime increased in the PAO-JP2 strain when iron was depleted. Tobramycin achieved the best bactericidal effect in biofilms. Viable counts were reduced by one log under iron-depleted conditions in all three strains when tobramycin reached 4 MIC and when ceftazidime and ciprofloxacin reached 8 MIC. CONCLUSIONS: This study suggests that once the biofilm is formed, iron depletion may only slightly promote the bactericidal effect of antibiotics on PAO1, PAO-DeltapilHIJK and PAO-JP2. Although these changes were relatively small, iron as one of the environmental factors should not be ignored when evaluating bactericidal effect of antibiotics. The combination of an iron chelator and antibiotics may have therapeutic value under certain bacterial growth conditions.


Subject(s)
Anti-Infective Agents/pharmacology , Biofilms/drug effects , Iron/metabolism , Plankton/drug effects , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/physiology , 2,2'-Dipyridyl/pharmacology , Biofilms/growth & development , Ceftazidime/pharmacology , Ciprofloxacin/pharmacology , Nutritive Value , Plankton/growth & development , Pseudomonas aeruginosa/genetics , Tobramycin/pharmacology
10.
Mol Plant ; 1(1): 167-77, 2008 Jan.
Article in English | MEDLINE | ID: mdl-20031923

ABSTRACT

Cryptochromes are blue-light receptors that mediate blue-light inhibition of hypocotyl elongation and blue-light stimulation of floral initiation in Arabidopsis. In addition to their blue-light-dependent functions, cryptochromes are also involved in blue-light-independent regulation of the circadian clock, cotyledon unfolding, and hypocotyl inhibition. However, the molecular mechanism associated with the blue-light-independent function of cryptochromes remains unclear. We reported here a comparative proteomics study of the light regulation of protein expression. We showed that, as expected, the protein expression of many metabolic enzymes changed in response to both blue light and red light. Surprisingly, some light-regulated protein expression changes are impaired in the cry1cry2 mutant in both blue light and red light. This result suggests that, in addition to mediating blue-light-dependent regulation of protein expression, cryptochromes are also involved in the blue-light-independent regulation of gene expression. Consistent with this hypothesis, the cry1cry2 mutant exhibited reduced changes of mRNA expression in response to not only blue light, but also red light, although the cryptochrome effects on the red-light-dependent gene expression changes are generally less pronounced. These results support a hypothesis that, in addition to their blue-light-specific functions, cryptochromes also play roles in the control of gene expression mediated by the red/far-red-light receptor phytochromes.


Subject(s)
Arabidopsis/genetics , Arabidopsis/metabolism , Cryptochromes/genetics , Cryptochromes/metabolism , Gene Expression Regulation, Plant/radiation effects , Light , RNA, Messenger/genetics , RNA, Plant/genetics , Arabidopsis/radiation effects , Arabidopsis Proteins/genetics , Arabidopsis Proteins/metabolism , Arabidopsis Proteins/radiation effects , Carbonic Anhydrases/genetics , Carbonic Anhydrases/metabolism , Carbonic Anhydrases/radiation effects , Cryptochromes/radiation effects , Deoxyribodipyrimidine Photo-Lyase/genetics , Deoxyribodipyrimidine Photo-Lyase/metabolism , Deoxyribodipyrimidine Photo-Lyase/radiation effects , Kinetics , Mutagenesis , Mutation , Seedlings/genetics , Seedlings/metabolism , Seedlings/radiation effects , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
11.
Physiol Behav ; 92(4): 702-7, 2007 Nov 23.
Article in English | MEDLINE | ID: mdl-17612582

ABSTRACT

The present work was designed to establish a novel animal model for motion sickness (MS) in rodents and to evaluate the effects of a combination of scopolamine and modafinil on MS with this novel method. It was found that the rats and mice presented several symptoms induced by rotation such as, piloerection, tremble, urinal and fecal incontinence. As the rats and mice are lack of emesis response to rotation, we used a score based on abovementioned symptoms as an index for the severity of MS in rodents. MS index was determined in 260 mice with this novel method. It was found that the distribution of MS index was normal (W=0.99; P=0.23. P>0.05 considered values' normal distribution). The effects of scopolamine on MS were studied in mice and rats. It was found that scopolamine significantly decreased MS index at the dose of 0.3 mg/kg in mice and 1.0 mg/kg in rats. Finally, the effects of a combination of scopolamine and modafinil were observed with this novel method in rats. It was found that the efficacy of the combination (5.0+5.0 mg/kg) was greater than the single drugs (10 mg/kg). Even the smallest dose of the combination (0.5+0.5 mg/kg) had a similar effect to large dose of scopolamine or modafinile when they were used alone. In conclusion, this animal model is suitable for MS study in rats and mice and the combination of scopolamine and modafinil might be a new method to treat or prevent MS.


Subject(s)
Benzhydryl Compounds/therapeutic use , Central Nervous System Stimulants/therapeutic use , Disease Models, Animal , Motion Sickness/prevention & control , Muscarinic Antagonists/therapeutic use , Scopolamine/therapeutic use , Animals , Defecation/drug effects , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Male , Mice , Modafinil , Motion Sickness/complications , Piloerection/drug effects , Rats , Rats, Sprague-Dawley , Tremor/etiology , Tremor/prevention & control , Urination/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...